Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Protalix BioTherapeutics is an Israeli biopharmaceutical company commercializing plant cell-based recombinant therapeutic proteins, primarily Elelyso (taliglucerase alfa) for Gaucher disease. The company's proprietary ProCellEx platform produces complex proteins in tobacco plant cells, offering potential cost advantages versus traditional mammalian cell culture. Revenue is concentrated in Elelyso royalties from Pfizer's ex-US distribution and direct US sales through Chiesi USA, with recent revenue decline reflecting competitive pressures in the small Gaucher disease market.
Protalix generates revenue through a hybrid model: (1) royalty payments from Pfizer on ex-US Elelyso sales, providing high-margin recurring income with no direct sales expense; (2) product supply and profit-sharing from Chiesi USA for US market distribution; (3) potential milestone payments from development partnerships. The ProCellEx plant-based manufacturing platform theoretically offers 50-70% lower production costs versus CHO cell systems, though this advantage is partially offset by limited scale. Pricing power is constrained by competition from Sanofi's Cerezyme and Takeda's VPRIV in the ~6,000 patient global Gaucher market, with Elelyso positioned as a biosimilar-like alternative at 10-15% discount.
Elelyso market share trends in US and Brazil (key markets with pricing flexibility)
Clinical trial readouts for PRX-102 (pegunigalsidase alfa) in Fabry disease - potential $500M+ market opportunity
Partnership announcements or milestone payments from Chiesi or other collaborators
Regulatory approvals in new geographies for Elelyso or pipeline candidates
Manufacturing capacity utilization and cost-per-gram improvements in ProCellEx platform
Gaucher disease market erosion as substrate reduction therapy (Sanofi's Cerdelga oral) gains share versus enzyme replacement therapy, potentially reducing Elelyso's $60-80M annual revenue base by 20-30% over 5 years
Gene therapy approaches (AVR-RD-01, others) in clinical development could render enzyme replacement obsolete by 2028-2030, creating existential risk to core franchise
ProCellEx platform has not achieved broad adoption beyond Elelyso despite 15+ years of development, limiting platform value and partnership appeal
Sanofi's Cerezyme maintains 60%+ market share with strong physician relationships and 25-year safety record; Elelyso positioned as third-line option in most markets
Takeda's VPRIV and potential biosimilars entering market could compress pricing 15-25%, eroding already thin 7.3% operating margins
PRX-102 Fabry program faces entrenched competition from Takeda's Replagal and Sanofi's Fabrazyme, requiring superiority data (not just non-inferiority) for meaningful uptake
Near-zero free cash flow ($6M operating cash flow, minimal capex) with $200M market cap implies 18-24 month cash runway at current burn rate, creating financing risk if pipeline milestones slip
Revenue decline of 18.5% YoY and net income drop of 64.7% indicate deteriorating unit economics; further market share losses could force dilutive capital raise
Dependence on Pfizer and Chiesi partnerships (80%+ of revenue) creates counterparty concentration risk; contract renegotiations in 2026-2027 could materially impact economics
low - Rare disease therapeutics demonstrate minimal GDP correlation as Gaucher disease treatment is medically necessary and typically reimbursed by government or private insurance regardless of economic conditions. Patient switching costs are high due to established treatment protocols. However, government healthcare budget pressures in key markets (Brazil, Israel) during recessions can delay reimbursement approvals or impose price cuts.
Rising rates create moderate headwinds through two channels: (1) higher discount rates compress valuation multiples for pre-revenue pipeline assets, particularly PRX-102 which represents significant option value; (2) increased cost of capital for potential partnerships or licensing deals. With minimal debt (0.15 D/E), financing costs are negligible. The 3.03 current ratio provides adequate liquidity buffer, but near-zero free cash flow means external financing sensitivity increases if rates remain elevated.
Minimal direct credit exposure as revenue is concentrated with investment-grade counterparties (Pfizer, Chiesi). However, hospital and specialty pharmacy payment cycles in emerging markets (Brazil, Russia) can extend to 90-120 days during credit tightening, impacting working capital. Reimbursement risk increases if government payers face fiscal stress.
growth/speculative - The 101.4% six-month return and 57.7% three-month surge indicate momentum-driven trading, likely tied to PRX-102 clinical catalysts or partnership speculation. Small $200M market cap attracts biotech-focused funds and retail investors seeking binary event exposure. Minimal institutional ownership given lack of profitability scale and single-product revenue concentration. Not suitable for value or income investors due to business model risks and zero dividend.
high - Micro-cap biotech with binary clinical catalysts, partnership-dependent revenue model, and thin trading volume creates 40-60% annualized volatility. Stock moves 10-20% on clinical updates, partnership announcements, or quarterly earnings misses. Recent 18.3% one-year return masks significant intra-year drawdowns. Beta likely 1.5-2.0x versus biotech indices.
